このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

CAR-T in Relapsed/Refractory Multiple Myeloma

2026年7月4日 更新者:Dr. Zaineb Akram

Pilot, Open-Label, Single-Arm Study of Autologous BCMA-Directed CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma in Pakistan

The treatment options for multiple myeloma have evolved significantly over the years, providing patients with a range of therapies tailored to their specific circumstances. The choice of treatment often hinges on various factors, including the aggressiveness of the disease, individual prognostic indicators like genetic markers, the overall physical condition of the patient, and any pre-existing health issues that may affect treatment decisions. Current therapeutic strategies include several classes of drugs, each working through different mechanisms. Proteasome inhibitors (PIs) disrupt the protein degradation process within myeloma cells, thereby promoting their death. Immunomodulatory drugs (IMiDs) modulate the immune system and inhibit tumor growth by enhancing the body's natural anti-cancer responses. Monoclonal antibodies specifically target cancer cells, marking them for destruction by the immune system. In cases where patients are eligible, autologous stem cell transplantation remains a viable option, offering the potential for long-term remission by replacing damaged bone marrow with healthy stem cells from the patient's own body.

Despite these advancements, multiple myeloma continues to present significant challenges, as it often recurs even after initial successful treatment and remains an incurable disease. This highlights the urgent need for innovative therapeutic strategies that can effectively address resistance to existing treatments, ultimately aiming to improve patient outcomes and survival rates.

調査の概要

詳細な説明

Multiple myeloma is characterized by the synthesis of monoclonal immunoglobulin (Ig) proteins or their fragments, known as M proteins, which have lost their biological functionality. (Kyle & Rajkumar, 2008; Palumbo & Anderson, 2011).

The proliferation of multiple myeloma cells results in the gradual displacement of normal bone marrow hematopoietic precursors, which are essential for the production of blood cells. This displacement not only hampers the normal hematopoiesis process but also leads to an overproduction of M-proteins, which can have detrimental effects on the body's systems. Key characteristics of multiple myeloma include osteolytic lesions (areas of bone destruction that can lead to fractures and significant pain). Patients often experience anemia due to the impaired production of red blood cells, making them more prone to fatigue and weakness. Moreover, the disease can significantly increase susceptibility to infections, as the immune system becomes compromised. Additional complications include hypercalcemia (characterized by abnormally high calcium levels in the blood), which can lead to nausea and confusion. Renal insufficiency or failure is another serious consequence, often arising from the effects of M-proteins on kidney function. Lastly, neurological complications can occur, manifesting as various symptoms ranging from peripheral neuropathy to more severe neurological deficits. Collectively, these manifestations highlight the complex and multifaceted impact of multiple myeloma on patients' health. (Korde et al., 2011; Palumbo & Anderson, 2011) In the year 2022, a total of 187,952 cases of Multiple Myeloma (MM) were documented across the globe, representing approximately 0.94% of all cancer cases reported internationally. This hematological malignancy exhibits notable geographical variations in its incidence rates. Notably, Asia accounted for the highest number of cases, with 73,870 reported instances, which corresponds to 39.3% of the global total. Europe and Northern America followed, with 50,092 cases (26.7%) and 37,050 cases (19.7%), respectively. Among the countries in the Eastern Mediterranean Region (EMRO), Pakistan has reported the highest rates of incidence (25.3%) and mortality (26.3%) for Multiple Myeloma (MM). In Pakistan, there were 1,846 new cases of Multiple Myeloma and 1,616 deaths attributed to this disease. These statistics highlight the clinical and epidemiological importance of MM both regionally and globally. They emphasize the ongoing need for research and healthcare strategies aimed at improving patient outcomes and understanding the factors contributing to the incidence and mortality of this complex disease. (Global Cancer Observatory, 2024).

Figure 01: Absolute numbers, Incidence of Multiple Myeloma in EMRO, both sexes, in 2022 (Global Cancer Observatory, 2024).

Figure 02: Absolute numbers, Mortality rate due to Multiple Myeloma in EMRO, both sexes, in 2022 (Global Cancer Observatory, 2024).

The treatment options for multiple myeloma have evolved significantly over the years, providing patients with a range of therapies tailored to their specific circumstances. The choice of treatment often hinges on various factors, including the aggressiveness of the disease, individual prognostic indicators like genetic markers, the overall physical condition of the patient, and any pre-existing health issues that may affect treatment decisions. Current therapeutic strategies include several classes of drugs, each working through different mechanisms. Proteasome inhibitors (PIs) disrupt the protein degradation process within myeloma cells, thereby promoting their death. Immunomodulatory drugs (IMiDs) modulate the immune system and inhibit tumor growth by enhancing the body's natural anti-cancer responses. Monoclonal antibodies specifically target cancer cells, marking them for destruction by the immune system. In cases where patients are eligible, autologous stem cell transplantation remains a viable option, offering the potential for long-term remission by replacing damaged bone marrow with healthy stem cells from the patient's own body.

Despite these advancements, multiple myeloma continues to present significant challenges, as it often recurs even after initial successful treatment and remains an incurable disease. This highlights the urgent need for innovative therapeutic strategies that can effectively address resistance to existing treatments, ultimately aiming to improve patient outcomes and survival rates.

4.2. BCMA B Cell Maturation Antigen (BCMA), also known as TNFRSF17, is a vital membrane protein intricately involved in the survival and proliferation of B lineage cells. This essential protein interacts with two key ligands: the proliferation-inducing ligand (APRIL) and the B-cell activating factor (BAFF). Both ligands play a crucial role in promoting the growth and longevity of plasma cells, which are critical components of the immune system (Tai & Anderson, 2015).

Recent research has highlighted the significant therapeutic potential of targeting BCMA as a treatment strategy for multiple myeloma (MM). Advances in this domain have led to the development of innovative BCMA-targeted therapies, including engineered CAR T-cell therapy and bispecific T-cell engagers. These groundbreaking approaches have demonstrated impressive efficacy in early-phase clinical trials, resulting in durable responses among patients with advanced, heavily pre-treated MM (Patel et al., 2004; Avery et al., 2003).

4.3. CAR-T Therapy The Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a groundbreaking advancement in the field of immunotherapy, specifically designed to harness the patient's own immune system to target and eliminate cancer cells. This innovative approach involves genetically modifying a patient's T cells so they can express a chimeric antigen receptor that specifically recognizes antigens present on the tumor cells.

Mechanism of Action The CAR-T process typically begins with the collection of T cells from the patient through a procedure known as apheresis. The collected T cells are then genetically engineered in a laboratory setting to produce Chimeric Antigen Receptors (CARs) that can recognize specific cancer markers, such as CD19, in B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma. Once engineered, these CAR-T cells are expanded in number and subsequently infused back into the patient. Upon reintroduction, the CAR-T cells patrol the body for cancer cells expressing the target antigen, initiating an immune response that can lead to cellular lysis of the malignant cells (June et al., 2018).

Clinical Efficacy CAR-T therapy has shown remarkable success, particularly in hematologic malignancies. For example, studies have reported overall response rates (ORR) exceeding 80% in patients with relapsed or refractory ALL after treatment with CAR-T cells targeting CD19 (Kymriah®) (Schuster et al., 2019). Similarly, in patients with large B-cell lymphoma, the CAR-T product axicabtagene ciloleucel (Yescarta®) also demonstrated impressive efficacy, with a median progression-free survival of 6.5 months and an ORR of 82% (Zuma-1 trial) (Zuma et al., 2017).

研究の種類

介入

入学 (推定)

10

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

  • 名前:Maryam Khan, MBBS, MRCP(UK), FCPS (Cl Haem)
  • 電話番号:+923366395758

研究場所

    • Punjab Province
      • Rawalpindi、Punjab Province、パキスタン、46000
        • 募集
        • National University of Medical Sciences, Clinical Trial Unit
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Tariq Ghafoor, MBBS,FCPS,FRCP(Ire),FRCP(Glas)
        • 副調査官:
          • Raheel Iftikhar, MBBS,FCPS(Med),FCPS(Cl Haem)
        • 副調査官:
          • Hammad Javed, MBBS,FCPS(Med), FCPS(Cl Haem)
        • 副調査官:
          • Memoona Khan, MBBS, FCPS (Haem)
        • 副調査官:
          • Aamir Aslam Awan, MBBS,FCPS(Paeds)
        • 副調査官:
          • Nadia Sial, PhD
        • 副調査官:
          • Arif Sadiq, MBBS,FCPS(Haem),FCPS(CL Haem)
        • 副調査官:
          • Saleem Ahmed Khan, MBBS,FCPS
        • 副調査官:
          • Babar Saeed Khan, MBBS

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria

  1. Male and female participants of age 18 years and above.
  2. Patients with a confirmed diagnosis of multiple myeloma according to IMWG diagnostic criteria.
  3. Received at least 3 prior multiple myeloma treatment lines of therapy or are double refractory to an IMiD and PI (refractory multiple myeloma as defined by IMWG consensus criteria). Note: induction with or without hematopoietic stem cell transplant and with or without maintenance therapy is considered a single line of therapy.
  4. Measurable disease at Screening as per IMWG criteria.
  5. ECOG Performance Status grade of 0 to 2.
  6. Adequate organ function: ANC/platelets thresholds (unless cytopenias attributable to MM), LVEF ≥45%, adequate oxygenation; hepatic/renal criteria specified in Section 10.
  7. Negative pregnancy test for women of childbearing potential; agreement to effective contraception.
  8. Patients giving written informed consent to participate in the study after a full understanding of the implications and constraints of the study protocol.
  9. Understand the content of the ICF, and voluntarily sign the ICF (If the participant is unable to sign the ICF on their own due to illiteracy, an impartial witness is needed).
  10. The subject can understand the research process and is willing and able to comply with all research proposals and other requirements of the study.
  11. Willing and able to adhere to the prohibitions and restrictions specified in this protocol.

Exclusion Criteria

1. Patients who will meet any of the following criteria will not be eligible to participate in the study.

  1. Prior treatment with CAR-T therapy directed at any target. Any therapy that is targeted to BCMA.
  2. Known active, or prior history of central nervous system (CNS) involvement, or exhibits clinical signs of meningeal involvement of multiple myeloma.
  3. Stroke or seizure within 6 months of signing the ICF.
  4. Uncontrolled active infection, including uncontrolled bacterial or fungal infection; active uncontrolled HBV/HCV/HIV.
  5. Clinically significant cardiac disease (e.g., NYHA III/IV, recent MI), or severe pulmonary disease.
  6. Recent allogeneic HSCT with active GVHD or ongoing immunosuppression.
  7. Pregnant or breast-feeding, or planning to become pregnant while enrolled in this study or within 1 year after receiving study treatment.
  8. Any other circumstances that would impair the ability of the participant to receive or tolerate the planned treatment at the investigational site, to understand informed consent, or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.

    -

    Exclusion Criteria:

    -

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
他の:CAR-T arm

6.2. Screening Phase During the Screening period, all participants will be asked to provide written consent for study participation and will be screened for study eligibility within 28 days before apheresis. Safety criteria that must be met before starting apheresis are presented in Section 8.1.1.

If an assessment was performed as part of the participant's routine clinical evaluation and not specifically for this study, it does not need to be repeated after signed informed consent has been obtained, provided the assessments fulfill the study requirements and are performed within the specified timeframe before the first dose of study treatment. Retesting of abnormal screening values that lead to exclusion is allowed only once during the screening phase (to reassess eligibility). The last result obtained before apheresis will be used to determine eligibility. Subjects who do not meet all inclusion criteria or who meet an exclusion criterion may, at the discretion of the investigator,

CAR-T therapy will be given

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Assess Safety /tolerability and feasibility of manufacturing and delivering the product
時間枠:From enrolment to 1 years after infusion of the product
incidence/severity of AEs including CRS/ICANS (ASTCT grading), DLTs through Day +28
From enrolment to 1 years after infusion of the product

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディチェア:Maryam Khan, MBBS, MRCP (UK), FCPS(Cl Haem)、National University of Medical Sciences
  • 主任研究者:Tariq Ghafoor、National University of Medical Sciences

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年6月1日

一次修了 (推定)

2027年12月31日

研究の完了 (推定)

2027年12月31日

試験登録日

最初に提出

2026年6月27日

QC基準を満たした最初の提出物

2026年7月4日

最初の投稿 (実際)

2026年7月8日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月8日

QC基準を満たした最後の更新が送信されました

2026年7月4日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

IPD will be shared on request by email.

IPD 共有時間枠

after 31st December 2027 till 31st December 2028

IPD 共有アクセス基準

Access will be given by requesting PI by email

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する